Company Overview - The company, Vaimo Biotechnology (Zhejiang) Co., Ltd., focuses on the ophthalmology sector and aims to become a global leader in innovative ophthalmic therapies [4] - Established in 2016, the company has developed a competitive and differentiated product pipeline addressing various ophthalmic indications with significant unmet clinical needs [4] Core Products - VVN461 (High Dose) is a novel dual-target inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), currently undergoing Phase III clinical trials in China for non-infectious anterior uveitis (NIAU) [4][6] - VVN001 is a second-generation LFA-1 antagonist designed for treating dry eye disease (DED), with ongoing Phase III clinical trials in China [4][9] Clinical Development - VVN461 has shown comparable anti-inflammatory efficacy to corticosteroids in head-to-head Phase II trials, with a breakthrough therapy designation granted by the National Medical Products Administration (NMPA) [7] - VVN001 demonstrated higher efficacy and safety compared to the standard treatment cyclosporine A (CsA) in clinical trials, improving patient experience and compliance [10] Financial Information - For the nine months ending September 30, 2024, the company reported other income and gains of approximately RMB 8.572 million, with research and development expenses of about RMB 128.261 million [11] - The company incurred losses of approximately RMB 201.535 million for the fiscal year ending 2024 [12] Industry Overview - The global ophthalmic drug market is estimated to reach USD 41.6 billion in 2024, with a projected compound annual growth rate (CAGR) of 2.8% from 2024 to 2029, driven by an aging population and increasing prevalence of eye diseases [13] - The Chinese ophthalmic drug market is expected to grow from USD 2.7 billion in 2020 to USD 4.1 billion in 2024, with a CAGR of 10.8% [16]
眼科企业维眸生物递表港交所 拥有两款核心产品
Zhi Tong Cai Jing·2026-02-13 05:41